NCT03746080 - Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

May 31, 2022

Study Completion Date

July 31, 2027

Conditions

GlioblastomaGlioblastoma With Primitive Neuronal ComponentGliosarcomaMalignant GliomaOligodendroglial Component Present

Interventions

DRUG

Plerixafor

Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation

DRUG

Temozolomide

Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.

RADIATION

Whole-Brain Radiotherapy (WBRT)

Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations

RADIATION

Radiation Therapy

Radiotherapy consists of 30 Gy in 15 fractions

Trial Locations (1)

94304

Stanford Cancer Institute Palo Alto, Palo Alto